Immune-Related Adverse Events in the Setting of PD-1/L1 Inhibitor Combination Therapy

Abstract

In 2018, a multi-disciplinary workshop was held at the Massachusetts General Hospital to discuss challenges in defining, diagnosing, and treating immune-related adverse events (irAE), including those that occur in patients administered PD-1/L1 inhibitor combination therapy. In this commentary, the workshop participants present a clinical case that illustrates the complexity of irAE diagnosis and management in a patient receiving PD-1/L1 combination therapy, summarize the current state of PD-1/L1 combination therapy, and discuss challenges and opportunities for the evaluation of irAEs as these combinations become more widely used to treat patients with cancer.